Program
TQF6422
A development code. Also written as “TQF6422 Injection”.
Its studies are mostly in Obesity, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 11 open or running | phase 1since Aug 26, 2026 | Aug 26, 2026 | Jun 2028phase 1 · NCT07794111 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 26, 2026First study: phase 1 study in ObesityFirst studyNCT07794111 · 108 planned · China
Ahead
- Jun 2028Primary completion: phase 1 study in ObesityNCT07794111
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07794111Obesity · China | 1 | Not yet recruiting | Jun 2028 | 108 |
How it is read
Names in the registry
- “TQF6422 Injection”, 1 entry
Codes read as this program: TQF6422.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.